Healthcare entity
Of the tracked stories, 1 of 2 also mention Ambros Therapeutics, the most common co-covered peer. The 20-day window averages about 0.7 stories each week. acquisition accounts for 1 of the 2 tracked stories, while 1 other category carries the remainder.
Last mentioned: Aug 22, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Of the tracked stories, 1 of 2 also mention Ambros Therapeutics, the most common co-covered peer. The 20-day window averages about 0.7 stories each week. acquisition accounts for 1 of the 2 tracked stories, while 1 other category carries the remainder. Source depth averages 2 original sources per story, versus 2.3 across the same-window beat baseline. At 5.5, the average consequence score sits below the same-window beat average of 5.6. Janus Henderson Investors appears in 2 tracked Healthcare stories published from August 3, 2026 through August 22, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 229 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Janus Henderson Investors. Shared-story counts are live from our verified record — not editorial picks.
Cash runway into first half of 2029
Proceeds from the $150 million private placement are expected to fund a planned NDA submission and operations into the first half of 2029.
CRPS-RISE Phase 3 topline results expected
Ambros expects to report topline results from the pivotal CRPS-RISE trial evaluating neridronate in warm CRPS-1.
Merger and $150M financing announced
Werewolf Therapeutics and Ambros Therapeutics announce a definitive all-stock merger and an oversubscribed $150 million private placement.
The Werewolf-Ambros merger creates a Nasdaq-listed company focused on neridronate for CRPS-1, an under-served pain indication affecting 65,000 newly diagnosed U.S. patients yearly. A $150 million financing funds a 270-patient pivotal Phase 3 trial with topline data expected in 2028.
Source: rttnews.com · Investing South Africa
After a turbulent 2025 marked by cyberattack fallout and operational pressures, UnitedHealth Group is regaining its footing. A key management change has reignited confidence, and the company’s stock is now a top contributor to a major growth fund, signaling a broader sector recovery.
Janus Henderson Investors is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
